Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

Advocate for several Medicare & Medicaid provisions in the CARES Act (H.R. 748), including a delay of Medicare sequestration cuts, a delay of the Medicare Fiscal Accountability Rule and Medicaid disproportionate share hospital (DSH) cut relief.
Support increased Federal Medical Assistance Percentages (FMAP) and FMAP flexibility at the state level in the Families First Coronavirus Response Act (H.R. 6201) and the CARES Act (H.R. 748).
Advocate for federal childcare benefits for members of the health care workforce.
Advocate for increasing borrowing limits on SBA loans and ensuring health care providers are eligible.
Support direct funding for health care providers treating COVID-19 patients, including funding through the Hospital Preparedness Program.
Support funding and efforts to ensure health care providers have access to essential materials, such as PPE, for COVID-19 response and readiness.
Advocate for changes to indirect medical education payments to account for COVID-19 response efforts.
Advocate for direct Federal funding for state and local governments during the COVID-19 crisis.
Discuss the distribution methodology for the Public Health and Social Services Emergency Fund with the White House, HHS, CMS and Congressional staff.
Discuss issues related to Medicare accelerated payments with White House, HHS, CMS and Congressional staff.
Advocate for continued Federal funding for New York States DSRIP program.
Discuss Medicare and Medicaid issues with the CMS Administrator.
Discuss COVID-19 response with White House staff and HHS leadership, including the HHS Secretary.
Discuss GNYHA's legislative priorities with Congressional staff: a delay of cuts to Medicaid DSH funding (support), site-neutral policies (oppose), 340B drug discount program (support), expanding federal graduate medical education programs (support), funding to address the opioid crisis (support), funding for hospital infrastructure (support), the Affordable Care Act (support), and liver allocation reforms (support).
Discuss the need to reform the United States' liver allocation system with Congressional staff/members, HHS, HRSA, UNOS and OPTN.
Oppose several provisions in the White House's FY 2021 budget blueprint including cuts and changes to GME funding, site-neutral policies, changes to Medicare UCP and bad debt, Medicare post-acute care payments, wage index adjustments, and other Medicaid cuts. Support for the Medical liability provisions in the budget.
Educate Congressional staff and lawmakers on Medicare for All.
Support graduate medical education funding through the Medicare program, including support for the Resident Physician Shortage Reduction Act (S. 348/H.R. 1763) and the Opioid Workforce Act (H.R. 3414/S. 2439).
Discuss technical assistance regarding the Opioid Workforce Act (H.R. 3414/S. 2439) with committee staff.
Discuss the Prescription Drug Pricing Reduction Act of 2019 (S. 2543) with Congressional staff and committee staff.
Support surprise billing legislation reform and work with committee and Congressional staff on a range of issues. Discussed several bills including: Protecting People from Surprise Medical Bills Act (H.R. 3502), Lower Health Care Costs Act (S. 1895), No Surprises Act (H.R. 3630) and Consumer Protections Against Surprise Medical Bills Act of 2020 (H.R. 5826).
Discussed the inclusion of surprise billing legislation in COVID-19 response legislation.
Discuss New York State's Partnership for Patients initiative with CMS contract officers.
Discuss GME rural training tracks and possible reforms with Congressional staff.
Discuss the ET3 model with staff from CMMI.
Discuss the Medicare GME program, including issues related to oversight and transparency, with congressional staff.
Spoke with CMS to review Medicare DGME policy (42 CFR 413.75) on residency counting issues
Discuss provisions in the CARES Act (H.R. 748) related to health care provider liability and immunity with Congressional and committee staff.
Attend cybersecurity briefing related to foreign threats with FBI.
Discuss issues concerning DSH hospitals with the Executive Branch.
Discuss Medicare and Medicaid issues with the CMS Administrator.
Discuss Lower Drug Costs Now Act (H.R.3) with Congressional staff.
Discuss issues related to telehealth and HIT with staff from CMS, the White House and Congressional staff.
Discuss drug shortages related to the COVID-19 crisis with Congressional and Administration staff.
Coordinate with ASPR, the Department of Defense, FEMA and the FDA on COVID-19 response efforts.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Health Resources & Services Administration (HRSA), Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB), White House Office, Medicare Payment Advisory Commission (MedPAC), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), Substance Abuse & Mental Health Services Administration (SAMHSA), Executive Office of the President (EOP), President of the U.S., Congressional Budget Office (CBO), Federal Bureau of Investigation (FBI), Defense - Dept of (DOD), Small Business Administration (SBA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Advocate for several Medicare & Medicaid provisions in the CARES Act (H.R. 748), including a delay of Medicare sequestration cuts, a delay of the Medicare Fiscal Accountability Rule and Medicaid disproportionate share hospital (DSH) cut relief.
Support increased Federal Medical Assistance Percentages (FMAP) and FMAP flexibility at the state level in the Families First Coronavirus Response Act (H.R. 6201) and the CARES Act (H.R. 748).
Advocate for changes to indirect medical education payments to account for COVID-19 response efforts.
Discuss issues related to Medicare accelerated payments with White House, HHS, CMS and Congressional staff.
Advocate for continued Federal funding for New York States DSRIP program.
Discuss Medicare and Medicaid issues with the CMS Administrator.
Discuss COVID-19 response with White House staff and HHS leadership, including the HHS Secretary.
Discuss GNYHA's legislative priorities with Congressional staff: a delay of cuts Medicaid DSH funding (support), site-neutral policies (oppose), 340B drug discount program (support), expanding federal graduate medical education programs (support), funding to address the opioid crisis (support), and the Affordable Care Act (support).
Oppose several provisions in the White House's FY 2021 budget blueprint including cuts and changes to GME funding, site-neutral policies, changes to Medicare UCP and bad debt, Medicare post-acute care payments, wage index adjustments, and other Medicaid cuts.
Educate Congressional staff and lawmakers on Medicare for All.
Support graduate medical education funding through the Medicare program, including support for the Resident Physician Shortage Reduction Act (S. 348/H.R. 1763) and the Opioid Workforce Act (H.R. 3414/S. 2439).
Discuss technical assistance regarding the Opioid Workforce Act (H.R. 3414/S. 2439) with committee staff.
Discuss the Prescription Drug Pricing Reduction Act of 2019 (S. 2543) with Congressional staff and committee staff.
Discuss New York State's Partnership for Patients initiative with CMS contract officers.
Discuss GME rural training tracks and possible reforms with Congressional staff.
Discuss the ET3 model with staff from CMMI.
Discuss the Medicare GME program, including issues related to oversight and transparency, with congressional staff.
Spoke with CMS to review Medicare DGME policy (42 CFR 413.75) on residency counting issues
Discuss issues concerning DSH hospitals with the Executive Branch.
Discuss Medicare and Medicaid issues with the CMS Administrator.
Discuss Lower Drug Costs Now Act (H.R.3) with Congressional staff.
Discuss issues related to telehealth and HIT with staff from CMS, the White House and Congressional staff.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), President of the U.S.

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

Discuss issues related to group purchasing organizations (GPOs) with Congressional staff and members.
Discuss several pieces of legislation with Congressional staff including: the CREATES Act (H.R. 965/S. 340) (support), the Fast Access for Safe & Timely Generics Act (H.R. 985) (support), the Protecting Consumer Access to Generic Drugs Act (H.R. 1499) (support), the Fair and Immediate Release of Generic Drugs Act (H.R. 1506) (support), the Orange Book Transparency Act (H.R. 1503) (support), the Purple Book Continuity Act (H.R. 1520) (support), and the Bringing Low-Cost Options and Competition While Keeping Incentives for New Generics Act (H.R. 938) (support).
Discuss the METRIC Act (H.R. 2296) with Congressional staff.
Discuss legislation to address drug shortages with Congressional staff and members, the MEDS Act (S. 2373) (support), advocate for its inclusion in the CARES Act (H.R. 748).
Discuss the Prescription Drug Pricing Reduction Act of 2019 (S. 2543) with Congressional staff and committee staff.
Discuss Lower Drug Costs Now Act (H.R.3) with Congressional staff.
Discuss drug shortages related to the COVID-19 crisis with Congressional and Administration staff.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

Oppose several provisions in the White House's FY 2021 budget blueprint including cuts and changes to GME funding, site-neutral policies, changes to Medicare UCP and bad debt, Medicare post-acute care payments, wage index adjustments, and other Medicaid cuts. Support for the Medical liability provisions in the budget.
Discuss proposed appropriations language related to OPTN/UNOS liver allocation reforms with Congressional staff and lawmakers.
Support the inclusion of funding for hospital infrastructure and workforce programs in appropriations legislation.
Support for the inclusion of provisions to delay the Medicaid DSH cuts in appropriations legislation.
Advocate for several Medicare & Medicaid provisions in the CARES Act (H.R. 748), including a delay of Medicare sequestration cuts, a delay of the Medicare Fiscal Accountability Rule and Medicaid disproportionate share hospital (n) cut relief.
Support increased Federal Medical Assistance Percentages (FMAP) and FMAP flexibility at the state level in the Families First Coronavirus Response Act (H.R. 6201) and the CARES Act (H.R. 748).
Advocate for federal childcare benefits for members of the health care workforce.
Support direct funding for health care providers treating COVID-19 patients, including funding through the Hospital Preparedness Program.
Support funding and efforts to ensure health care providers have access to essential materials, such as PPE, for COVID-19 response and readiness.
Advocate for direct Federal funding for state and local governments during the COVID-19 crisis.
Support graduate medical education funding through the Medicare program, including support for the Resident Physician Shortage Reduction Act (S. 348/H.R. 1763) and the Opioid Workforce Act (H.R. 3414/S. 2439), and its inclusion in appropriations legislative.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Executive Office of the President (EOP), President of the U.S.

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

Support for repealing the provisions related to SALT enacted in the Tax Cuts and Jobs Act.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
No Yes